Continuous infusion of a standard combination solution in the management of XXXX .

@entity13101 @entity1 @entity3747 @entity5838 @entity2741 @entity3489 @entity4053 @entity72488 @entity10041 @entity972 @entity6564 @entity4854 @entity413 @entity4144
BACKGROUND: @entity4144 , due to its effect on cardiac conductivity, is a potentially life-threatening electrolyte abnormality. Multiple therapeutic agents may be used alone or in combination for its prompt management. METHODS: We report on the safety and efficacy of continuous infusion of a solution containing fixed concentrations of @entity10041 , insulin, @entity413 and @entity13101 (HyperK-Cocktail) for the treatment of @entity4144 . This solution is prepared at our institution and is infused parenterally until the plasma @entity972 level stabilizes. Twenty-one consecutive @entity6564 @entity1 managed with HyperK-Cocktail on 23 occasions are reported. RESULTS: None of the subjects had intravenous extravasation injuries, @entity3489 , @entity3747 , @entity2741 or @entity5838 during HyperK-Cocktail infusion. Transient @entity4854 developed in nine subjects and @entity4053 in one subject. The decrease in serum @entity972 was similar in the initial hour when compared to prior studies using a beta-agonist and/or insulin and @entity413 ; a larger decrease was present from 2 to 8 h with the HyperK-Cocktail. The plasma @entity972 decreased by a mean of 1.0, 1.7, 2.1 and 2.1 mmol/ @entity72488 h, respectively. The mean serum @entity972 at hours 1-8 was significantly lower than the initial level. CONCLUSION: The results of our study demonstrated that HyperK-Cocktail is a safe and effective combination therapy for @entity1 with @entity4144 .
